Study Comparing Two-Point Versus Four-Point Methylene Blue Injection for Sentinel Lymph Node Mapping in Early Stage Endometrial Cancer

What this Trial Is About

This trial studies lymph node mapping in patients newly diagnosed with stage I endometrial cancer undergoing surgery. It compares a standard 2-point cervical injection of methylene blue dye with a newer 4-point injection method to see if increasing injection sites improves sentinel lymph node SLN detection rates. The research aims to provide detailed insights into whether the 4-point injection offers an advantage for better mapping success. Participants are randomly assigned to one of two groups one group receives injections at two cervix locations 3 and 9 oclock, and the other group receives injections at four different cervix sites 2, 4, 8, and 10 oclock. Both groups undergo the SLN mapping procedure using methylene blue dye to identify lymph nodes draining the uterus. This is a randomized controlled trial led by Dokuz Eylul University. During the study, researchers evaluate SLN detection rates, sensitivity and specificity of SLN biopsy for detecting metastases, and the rate of positive SLNs. They also monitor procedure duration, injection-related side effects, anatomical distribution of SLNs, and surgical complications. Participants are followed closely for one month to assess any complications and side effects related to the injection and surgery.

Comparison of Two-Position and Four-Position Cervical Injection Techniques for Sentinel Lymph Node Mapping in Endometrial Cancer Using Methylene Blue